KCI to Launch the V.A.C.VIA™, an Advanced Mobile Healing Technology

KCI para lançar o V.A.C.VIA™, uma tecnologia Healing móvel avançada

Press releases may be edited for formatting or style | May 03, 2010

V.A.C.Via™ Builds on Proven Clinical Research Behind Patented V.A.C.® Therapy System

V.A.C.® Therapy is the only wound care technology substantiated by 22 randomized controlled trials and more than 550 peer-reviewed articles. V.A.C.Via™ takes that science and makes the entire process-hospital to home-simpler, more mobile and outcome-driven.

Extremely lightweight, it increases mobility and provides a more discreet option for patients. Combined with virtually silent pump technology, all of V.A.C.Via's™ innovative features improve the continuity of care and patient compliance while delivering great outcomes through V.A.C.® Therapy's traditional mechanisms of action, including:

You don’t have to invest heavily in CT technology to achieve your Coronary CTA goals

Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.

* Removing exudate and potentially infectious material
* Stimulating perfusion
* Reducing edema
* Promoting formation of granulation tissue
* Protecting the wound bed and providing a closed, moist wound-healing environment

"V.A.C.Via™ is about innovation and outcomes," said Mike Genau, global president, KCI's Active Healing Solutions™ business unit. "Its mobile form and simple functionality deliver to the marketplace what's needed the most: a solution that reduces hospital costs and length of stay while getting patients well on their way to recovery by relying on a remarkable and clinically proven healing technology, V.A.C.® Therapy."

V.A.C.Via™ advances KCI's leadership position in negative pressure technology and is part of a broader product portfolio strategy to extend negative pressure's healing benefits to more patients and conditions. It follows the global launch of ABThera™ Open Abdomen Negative Pressure System in late 2009 and the European, Canadian and Australian launch of the Prevena™ Incision Management System - products that address open abdominal wounds and surgically closed incisions, respectively. KCI is ready to launch Prevena™ in the U.S., pending FDA clearance.

For more information about KCI please visit www.kci1.com.
About KCI

Kinetic Concepts, Inc. (NYSE:KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound healing, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's legacy spans more than three decades and is rooted in a passion for healing wounds and restoring lives around the world through innovative, clinically proven therapies. The Company employs 6,800 people and markets its products in 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.

Back to HCB News